Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Drugs Ethical Standards

 
 
Drug promotion can significantly influence the way medicines are prescribed, dispensed and used. It can lead to over-prescribing and poor quality  prescribing and medicine use which, in turn, can lead to increased risks of adverse effects and higher health-care costs. The World Health Organization established the Ethical Criteria for Medicinal Drug Promotion which defines promotion as "all informational and persuasive activities of manufacturers and distributors that affect the prescription, supply, purchase and/or use of medicinal drugs".
The Lebanese Ministry of Public Health worked on adapting these criteria to national circumstances with the help of all relevant stakeholders under the leadership of Dr. Walid Ammar- General Director of the ministry to have a comprehensive code of ethics to prevent the provision of inaccurate and misleading information and promote the rational use of medicines.
The code of ethics provides guidance for health professionals on how to manage their interactions with industry and guidance for industry about how to implement their marketing practices to establish transparency and accountability in pharmaceutical promotion.
The code is now ready to be launched after it was finalized as a result of a wide participatory process that lasted for 2 years with all relevant stakeholders
 
 

 
ATC Name B/G Ingredients Dosage Form Price
L04AD02 PROGRAF 5MG B Tacrolimus - 5mg 5mg Capsule L.L
B02BX06 HEMLIBRA BioTech Emicizumab - 30mg/ml 30mg/ml Injectable solution L.L
L01EA04 BOSULIF B Bosutinib - 400mg 400mg Tablet, film coated L.L
L01EA04 BOSULIF B Bosutinib - 500mg 500mg Tablet, film coated L.L
L04AX04 REVLIMID B Lenalidomide - 10mg 10mg Capsule L.L
B02BX05 REVOLADE B Eltrombopag Olamine - 50mg 50mg Tablet, film coated L.L
L01FF03 IMFINZI BioTech Durvalumab - 500mg/10ml 500mg/10ml Injectable solution L.L
L01EF01 PAPILLIO G Palbociclib - 100mg 100mg Capsule, hard L.L
L01EX05 STIVARGA B Regorafenib - 40mg 40mg Tablet, film coated L.L
L01FF03 IMFINZI BioTech Durvalumab - 500mg/10ml 500mg/10ml Injectable solution L.L
B02BD08 ARYOSEVEN RT BioTech Eptacog alfa - 1mg 1mg Injectable powder for solution+diluent L.L
L03AB07 RECIGEN 44 BioTech Interferon beta-1a - 44mcg/0.5ml 44mcg/0.5ml Injectable solution L.L
L01EB01 GEFITINIB BIOGARAN G Gefitinib - 250mg 250mg Tablet, coated L.L
A16AB04 FABRAZYME BioTech Agalsidase beta - 35mg 35mg Injectable powder for concentrate for solution L.L
L04AX04 LENOMA G Lenalidomide - 10mg 10mg Capsule, hard L.L
L04AX04 LENOMA G Lenalidomide - 25mg 25mg Capsule, hard L.L
L04AX04 LENOMA G Lenalidomide - 15mg 15mg Capsule, hard L.L
L04AB02 IXIFI BioTech Infliximab - 100mg 100mg Injectable powder for concentrate for solution L.L
B02BD04 BENEFIX BioTech Nonacog alfa (recombinant coagulation factor IX) - 500IU 500IU Injectable powder for solution+diluent L.L
L01FF04 BAVENCIO BioTech Avelumab - 200mg/10ml 200mg/10ml Injectable concentrate for solution L.L
L04AB01 ALTEBREL BioTech Etanercept - 50mg/1ml 50mg/1ml Injectable solution L.L
L01FF05 TECENTRIQ BioTech Atezolizumab - 1200mg 1200mg Injectable concentrate for solution L.L
L01EG02 EVEROLIMUS ARROW G Everolimus - 2.5mg 2.5mg Tablet L.L
L01EG02 EVEROLIMUS ARROW G Everolimus - 5mg 5mg Tablet L.L
L01EG02 EVEROLIMUS ARROW G Everolimus - 10mg 10mg Tablet L.L
L01EX01 SUTENT B Sunitinib maleate - 12.5mg 12.5mg Capsule L.L
L01EX01 SUTENT B Sunitinib maleate - 50mg 50mg Capsule L.L
L01XX24 ONCASPAR B Pegaspargase - 750U/ml 750U/ml Injectable powder for solution L.L
L01EL01 IMBRUVICA B Ibrutinib - 420mg 420mg Tablet, film coated L.L
L01XG01 BORTEZOMIB NEAPOLIS G Bortezomib - 3.5mg 3.5mg Injectable lyophilised powder for solution L.L
Sitemap
© Copyrights reserved to Ministry of Public Health 2025